Your browser doesn't support javascript.
loading
Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil.
Oliveira, Renato Almeida Rosa de; Mourão, Thiago Camelo; Santana, Thiago Borges Marques; Favaretto, Ricardo de Lima; Zequi, Stenio de Cassio; Guimarães, Gustavo Cardoso.
Affiliation
  • Oliveira RAR; Urology Department, Beneficência Portuguesa de São Paulo, São Paulo, Brazil; Instituto de Urologia, Oncologia e Cirurgia Robótica, São Paulo, Brazil. Electronic address: oliveira.rar@hotmail.com.
  • Mourão TC; Urology Department, Beneficência Portuguesa de São Paulo, São Paulo, Brazil; Instituto de Urologia, Oncologia e Cirurgia Robótica, São Paulo, Brazil.
  • Santana TBM; Urology Department, Beneficência Portuguesa de São Paulo, São Paulo, Brazil; Instituto de Urologia, Oncologia e Cirurgia Robótica, São Paulo, Brazil.
  • Favaretto RL; Urology Department, Beneficência Portuguesa de São Paulo, São Paulo, Brazil; Instituto de Urologia, Oncologia e Cirurgia Robótica, São Paulo, Brazil.
  • Zequi SC; Urology Department, AC Camargo Cancer Center - São Paulo, São Paulo, Brazil.
  • Guimarães GC; Instituto de Urologia, Oncologia e Cirurgia Robótica, São Paulo, Brazil; Surgical Oncology Department, Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Value Health Reg Issues ; 26: 89-97, 2021 Dec.
Article in En | MEDLINE | ID: mdl-34146776
ABSTRACT

INTRODUCTION:

Prostate cancer is one of the most common malignancies among men worldwide. Prostate-specific antigen (PSA) screening shows uncertain benefits and harms from clinical and economic perspectives, resulting in an important impact on healthcare systems. Because of nonstandardized studies and substantial differences among populations, data are still inconclusive.

OBJECTIVE:

The objective of this study was to carry out long-term cost-effectiveness and cost-utility analysis on the PSA-screened population from the service provider's perspective in the Brazilian population.

METHODS:

We performed a cost-effectiveness and cost-utility analysis using clinical outcomes obtained from 9692 men enrolled in the PSA screening program. Prostate cancer treatments, 5-year follow-up outcomes, and all related costs were examined. Data were compared with a nonscreened prostate cancer population to calculate incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR). ICER and ICUR were compared with the Brazilian-established willingness-to-pay (WTP) threshold (WTP = R$ 114 026.55).

RESULTS:

A total of 251 of 9692 men had a diagnosis of prostate cancer (2.6%), of which 90% had localized disease. Two hundred and five patients were treated as follows surgery (45.37%); radiation therapy (11.22%); radiation plus androgen deprivation therapy (21.95%); active surveillance (13.17%); exclusive androgen deprivation therapy (7.32%); and watchful waiting (0.98%). Two simulated cohorts were compared based on screening and nonscreening groups. Values obtained were-ICER of R$ 44 491.39 per life saved and ICUR of R$ 10 851.56 per quality-adjusted life year (QALY) gained-below the Brazilian WTP threshold and showed cost-effectiveness and cost-utility advantages.

CONCLUSION:

According to the Brazilian WTP, PSA screening is a cost-effective policy from a hospital and long-term perspective and should have more standardized studies developed in different populations and economies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Prostate-Specific Antigen Type of study: Diagnostic_studies / Health_economic_evaluation / Screening_studies Limits: Humans / Male Country/Region as subject: America do sul / Brasil Language: En Journal: Value Health Reg Issues Year: 2021 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Prostate-Specific Antigen Type of study: Diagnostic_studies / Health_economic_evaluation / Screening_studies Limits: Humans / Male Country/Region as subject: America do sul / Brasil Language: En Journal: Value Health Reg Issues Year: 2021 Type: Article